Genome methylation approach to search mechanisms of malignancy and new therapeutic targets in multiple myeloma
Project/Area Number |
15K09456
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Hematology
|
Research Institution | Sapporo Medical University |
Principal Investigator |
ISHIDA Tadao 札幌医科大学, 医学部, 研究員 (20305220)
|
Co-Investigator(Kenkyū-buntansha) |
池田 博 札幌医科大学, 医学部, 助教 (60570132)
丸山 玲緒 札幌医科大学, 医学部, 研究員 (60607985)
石黒 一也 札幌医科大学, 医学部, 研究員 (90784439)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 多発性骨髄腫 / エピジェネティクス / ヒストンメチル化 / メチル化 / エピジェネッティック / ゲノム |
Outline of Final Research Achievements |
DNA methylations and histone modifications are deeply involved in oncogenesis and inhibitors which target epigenetic modifications are used for cancer therapies. In this study, we aimed to clarify the histone methylation inhibitors which suppressed the survival of multiple myeloma (MM). As a result, we found that DOT1L inhibitors strongly repressed the proliferation of MM. Our results suggest DOT1L could be a therapeutic target in MM.
|
Report
(4 results)
Research Products
(7 results)
-
[Journal Article] Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.2016
Author(s)
Shimazaki C, Fuchida S, Suzuki K, Ishida T, Imai H, Sawamura M, Takamatsu H, Abe M, Miyamoto T, Hata H, Yamada M, Ando Y
-
Journal Title
Int J Hematol
Volume: 103
Issue: 1
Pages: 79-85
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.2016
Author(s)
Watanabe T, Tobinai K, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Kashihara T, Iida S.
-
Journal Title
Br J Haematol.
Volume: 172
Issue: 5
Pages: 745-756
DOI
Related Report
Peer Reviewed
-
-
-
[Presentation] The histone methyltransferase DOT1L is a potential therapeutic target in multiple myeloma2018
Author(s)
Kazuya Ishiguro, Hiroshi Kitajima, Takeshi Niinuma, Tadao Ishida, Reo Maruyama, Hiroshi Ikeda, Toshiaki Hayashi, Hajime Sasaki, Hideki Wakasugi, Koyo Nishiyama, Tetsuya Shindo, Eiichiro Yamamoto, Masahiro Kai, Yasushi Sasaki, Takashi Tokino, Hiroshi Nakase and Hiromu Suzuki
Organizer
Targeting DNA Methylation and Chromatin for Cancer Therapy
Related Report
-
-